Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma
Br J Haematol
.
2015 Feb;168(4):605-6.
doi: 10.1111/bjh.13128.
Epub 2014 Sep 19.
Authors
Philippe Moreau
1
,
Jean-Yves Mary
,
Michel Attal
Affiliation
1
Haematology Department, UMR 892, University Hospital, Nantes, France.
[email protected]
.
PMID:
25236408
DOI:
10.1111/bjh.13128
No abstract available
Keywords:
autologous stem cell transplantation; bortezomib; induction therapy; multiple myeloma.
Publication types
Letter
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Multiple Myeloma / drug therapy*